Vir Biotechnology, Inc. · NASDAQ:VIR
Vir Biotechnology — Q3 2023 Earnings Presentation
12 slides from Vir Biotechnology's earnings presentation, Nov 2, 2023
Slide 1: Corporate Overview
Corporate Overview November 2023
Slide 2: Legal Disclaimer
LEGAL DISCLAIMER Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the near-term financial performance of Vir Biotechnology, Inc. (the
Slide 3: Vir: Our Mission Matters More Than Ever
Vir: Our Mission Matters More Than Ever Vir is an immunology company focused on combining cutting-edge technologies to treat and prevent infectious diseases and other serious conditions Proven Track Record Important 2023 catalysts Long-term growth Financial Strength Delivered impactful Phase 2 data
Slide 4: Proven Track Record: Delivering Impactful Therapeutics
Proven Track Record: Delivering Impactful Therapeutics EBOLA COVID-19 Ebanga*: Recognized by the WHO for its global Xevudy (Sotrovimab**): Developed and health impact delivered in record time during a pandemic >2 million doses to treat patients *Discovered by Vir/NIH and marketed by Ridgeback Therap
Slide 5: Broad Pipeline: Driving Future Success
Broad Pipeline: Driving Future Success Treatment / Disease Area Product Candidate Pr e c l i n i c a l Ph a s e 1 Ph a s e 2 Ph a s e 3 A u t h o r i ze d Collaborator Pr o p h y l a x i s Hepatitis B VIR-2218 + PEG-IFN-⍺ Treatment Alnylam VIR-3434 ± VIR-2218 ± PEG-IFN-⍺1 Treatment Alnylam Alnylam/
Slide 6: Hepatitis B: In Pursuit of a Functional Cure
Hepatitis B: In Pursuit of a Functional Cure Unmet Need Vir Solution Multiple combination regimens to ~300M STOP the virus and CLEAR the infection people in the world live with VIR-3434 VIR-2218 chronic hepatitis B1 a neutralizing mAb HBV-targeted siRNA as a engineered for potential “backbone” immun
Slide 7: Hepatitis B: Progress in Our Pursuit
Hepatitis B: Progress in Our Pursuit VIR-2218-1001 TRIAL MARCH TRIAL PART A 24 Weeks following End of Treatment* End of Treatment** Sustained HBsAg loss Log HBsAg decline 16 % (N=5 of 31) ≥2.7 VIR-2218 + IFN VIR-3434 + VIR-2218 200 mg x13 Q4W 180 µg ≤44 weeks 200 mg 18 or 75 mg Cohorts 4&5 (N=31) C
Slide 8: Hepatitis Delta: Chronic Therapy for the Most Severe Form of Viral Hepatitis
Hepatitis Delta: Chronic Therapy for the Most Severe Form of Viral Hepatitis Unmet Need Vir Solution Evaluating chronic regimens to STOP the virus ~12M people in the world live with VIR-3434 VIR-2218 Well-understood MOAs • Entry inhibition • Dual knock-down of HBsAg chronic hepatitis delta1 MARKET L
Slide 9: Hepatitis Delta: Robust Biological Rationale for Vir Candidates
Hepatitis Delta: Robust Biological Rationale for Vir Candidates VIR-2218 VIR-3434 VIR-2218 + VIR-3434 Lowering infectious HDV in vitro* Lowering HDV RNA in vivo* Combination efficacy in vivo** HDV HDV Viremia HDV RNA *VIR-2218 and VIR-3434 therapy Is efficacious in preclinical models of hepatitis de
Slide 10: Next 18 Months: Multiple Anticipated Catalysts
Next 18 Months: Multiple Anticipated Catalysts 2023 Drug Candidates/Regimen Catalyst Timing VIR-2218 (siRNA) + VIR-3434 (mAb) +/- Hepatitis B Phase 2: End of Treatment clinical data (MARCH Part B) 4Q PEG-IFN-⍺ for 24 weeks VIR-3434 (mAb) monotherapy Hepatitis Delta VIR-2218 (siRNA) monotherapy Phase
Slide 11: Q3 2023: Financial Results
Q3 2023: Financial Results Three Months Ended September 30, Investor Relations – NASDAQ GS : VIR $ in thousands 2023 2022 Change Analyst Coverage: Total revenues Bank of America: Geoff Meacham $2,639 $374,557 $(371,918) Barclays: Gena Wang, Ph.D. Operating expenses: Cost of revenue 38 22,253 (22,215
Slide 12: Thank You
Thank You ad Powering the immune system to transform lives ©© 2023 2023 VirVir Biotechnology, Biotechnology, Inc. Inc.™ 12 12